Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
OVAS's Cash-to-Debt is ranked higher than
78% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. OVAS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OVAS' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
OVAS's Equity-to-Asset is ranked higher than
80% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OVAS: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
OVAS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.86  Med: 0.91 Max: 0.96
Current: 0.86
0.86
0.96
Interest Coverage No Debt
OVAS's Interest Coverage is ranked higher than
72% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OVAS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -3.47
Beneish M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -15881.51
OVAS's Operating Margin % is ranked lower than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. OVAS: -15881.51 )
Ranked among companies with meaningful Operating Margin % only.
OVAS' s Operating Margin % Range Over the Past 10 Years
Min: -25992.42  Med: -19199.28 Max: -12406.13
Current: -15881.51
-25992.42
-12406.13
Net Margin % -16132.26
OVAS's Net Margin % is ranked lower than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. OVAS: -16132.26 )
Ranked among companies with meaningful Net Margin % only.
OVAS' s Net Margin % Range Over the Past 10 Years
Min: -26432.85  Med: -19515.05 Max: -12597.24
Current: -16132.26
-26432.85
-12597.24
ROE % -66.92
OVAS's ROE % is ranked lower than
65% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. OVAS: -66.92 )
Ranked among companies with meaningful ROE % only.
OVAS' s ROE % Range Over the Past 10 Years
Min: -102.08  Med: -80.38 Max: -66.92
Current: -66.92
-102.08
-66.92
ROA % -60.12
OVAS's ROA % is ranked lower than
70% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. OVAS: -60.12 )
Ranked among companies with meaningful ROA % only.
OVAS' s ROA % Range Over the Past 10 Years
Min: -87.56  Med: -72.25 Max: -60.12
Current: -60.12
-87.56
-60.12
ROC (Joel Greenblatt) % -1213.38
OVAS's ROC (Joel Greenblatt) % is ranked lower than
64% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. OVAS: -1213.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OVAS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3579.1  Med: -2257.26 Max: -1166.9
Current: -1213.38
-3579.1
-1166.9
3-Year EBITDA Growth Rate 11.10
OVAS's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. OVAS: 11.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OVAS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.1 Max: 11.1
Current: 11.1
0
11.1
3-Year EPS without NRI Growth Rate 12.50
OVAS's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. OVAS: 12.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OVAS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 12.5
Current: 12.5
0
12.5
GuruFocus has detected 1 Warning Sign with OvaScience Inc OVAS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OVAS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

OVAS Guru Trades in Q3 2016

Paul Tudor Jones 29,326 sh (-31.68%)
» More
Q4 2016

OVAS Guru Trades in Q4 2016

Paul Tudor Jones 338,904 sh (+1055.64%)
» More
Q1 2017

OVAS Guru Trades in Q1 2017

Paul Tudor Jones 133,041 sh (-60.74%)
» More
Q2 2017

OVAS Guru Trades in Q2 2017

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ROCO:6566, ROCO:4109, XKRX:216400, OTCPK:NWBO, XCNQ:VGW, OTCPK:ORGS, ROCO:4186, NAS:LPTX, ASX:MEB, XKRX:002720, LSE:C4XD, NAS:AZRX, NAS:MBRX, NAS:PTI, XTAE:BVXV, AMEX:ATNM, LSE:MTPH, NAS:APVO, NAS:CAPR, NAS:NVIV » details
Traded in other countries:3OS.Germany,
Headquarter Location:USA
OvaScience Inc is a part of the healthcare sector. Its core area of operation involves commercialization of new fertility treatments for women using its patented technology.

OvaScience Inc is a biotechnology company focused on discovering, developing, and commercializing new fertility treatment options for women. The company's patented technology is based on a new fertility treatment option, "the newly discovered Egg precursor cells." Augment, the first treatment, is designed to improve egg health: Energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs. The OvaPrime treatment is a fertility treatment that could allow a woman to increase her own egg reserve. The OvaTure treatment is a potential next-generation fertility treatment that could allow a woman produce healthy, young, fertilizable eggs without hormone injections.

Top Ranked Articles about OvaScience Inc

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against OvaScience, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In OvaScience, Inc. (Nasdaq: OVAS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In OvaScience, Inc. To Contact The Firm
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against OvaScience, Inc. (OVAS) & Lead Plaintiff Deadline - May 29, 2017
IMPORTANT OVASCIENCE, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of purchasers of OvaScienc

Lead Plaintiff Deadline is May 26, 2017

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of OvaScience, Inc. (NASDAQ:OVAS) (“OvaScience”  or the  “Company”) securities during the period between January 8, 2015 and March  26, 2015, inclusive (the “Class  Period”).
Investors who have incurred losses in OvaScience, Inc. shares are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.  If  you have purchased shares of OvaScience, Inc. and would like to assist with the litigation process, you may, no later than May 26, 2017, request that the Court appoint you lead plaintiff of the proposed class. The filed complaint focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: the science behind AUGMENT, a treatment specifically designed to improve a patient's egg health, had not been scientifically validated;
 the Company was unable to achieve the success rates it claimed;
 the reasons why the Company moved its studies outside of the United States; and
 as a result, the Company’s profitability and prospects were false and misleading. On March 26, 2015, the Company disclosed that nine of the twenty-six women who received the AUGMENT treatment in Canada had achieved a pregnancy, a success rate of only approximately 35%.   Subsequently, on March 27, 2015, analysts for Leerink Partners LLC, stated that AUGMENT’s “[o]verall pregnancy rate appears less robust with a different denominator” and “the magnitude of AUGMENT benefit is unclear given no clear benchmarks and lack of standardized metrics.”   On March 28, 2015, the Company disclosed that only two of the eight women who received the AUGMENT treatment in Turkey achieved a pregnancy, a success rate of only 25%, which was comparable to the success rate achieved for women undergoing in vitro fertilization (“IVF”) without AUGMENT.   As a result of these disclosures, shares of OvaScience significantly declined, causing harm to investors. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. ## Follow the firm and learn about newly filed cases on Twitter and Facebook. ## Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Read more...
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In OvaScience, Inc. (OVAS) To Contact Brower Piven Before The Lead Plaintiff Deadline

STEVENSON, Md., March 29, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of OvaScience, Inc. (NASDAQ:OVAS) (“OvaScience” or the “Company”) securities during the period between January 8, 2015 and March 26, 2015, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until May 26, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in OvaScience securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the science behind AUGMENT, a treatment specifically designed to improve a patient’s egg health, had not been scientifically validated and the reasons why the Company moved its studies outside of the United States. According to the complaint, following a March 26, 2015 announcement that AUGMENT only had a success rate of 35% in a study in Canada, a March 27, 2015 report that the magnitude of AUGMENT benefit is unclear, and a March 28, 2015 announcement that the study in Turkey only showed a success rate of 25%, the value of OvaScience shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in OvaScience securities purchased on or after January 8, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In OvaScience, Inc. To Contact The Firm

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ:OVAS) of the May 26, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased OvaScience common stock between January 8, 2015 and March 26, 2015 (the “Class Period”).  The case, DAHHAN v. OvaScience, Inc. et al., No. 1:17-cv-10511 was filed on March 24, 2017. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the science behind AUGMENT, a treatment specifically designed to improve a patient's egg health, had not been scientifically validated; (2) the Company was unable to achieve the success rates it claimed; (3) the reasons why the Company moved its studies outside of the United States; and (4) as a result, the Company’s profitability and prospects were false and misleading. Specifically, on March 26, 2015, the Company disclosed that nine of the twenty-six women who received the AUGMENT treatment in Canada had achieved a pregnancy, a success rate of only approximately 35%.  Then, on March 27, 2015, analysts for Leerink Partners LLC, stated that AUGMENT’s “[o]verall pregnancy rate appears less robust with a different denominator” and “the magnitude of AUGMENT benefit is unclear given no clear benchmarks and lack of standardized metrics.”  Subsequently, on March 28, 2015, the Company disclosed that only two of the eight women who received the AUGMENT treatment in Turkey achieved a pregnancy, a success rate of only 25%, which was comparable to the success rate achieved for women undergoing in vitro fertilization (“IVF”) without AUGMENT.  Then, on March 30, 2015, an analyst for H.C. Wainwright & Co. questioned the Company’s AUGMENT data pregnancy rate calculation. As a result of these disclosures, shares of OvaScience significantly declined, causing harm to investors. Request more information now by clicking here: www.faruqilaw.com/OVAS. There is no cost or obligation to you. Take Action You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].  Faruqi & Faruqi, LLP also encourages anyone with information regarding OvaScience’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330


Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.63
OVAS's PB Ratio is ranked higher than
97% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. OVAS: 0.63 )
Ranked among companies with meaningful PB Ratio only.
OVAS' s PB Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.54 Max: 7.51
Current: 0.63
0.46
7.51
PS Ratio 107.69
OVAS's PS Ratio is ranked lower than
85% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. OVAS: 107.69 )
Ranked among companies with meaningful PS Ratio only.
OVAS' s PS Ratio Range Over the Past 10 Years
Min: 70  Med: 315.5 Max: 46970
Current: 107.69
70
46970
EV-to-EBIT 0.48
OVAS's EV-to-EBIT is ranked higher than
94% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. OVAS: 0.48 )
Ranked among companies with meaningful EV-to-EBIT only.
OVAS' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.9  Med: -1 Max: 0.8
Current: 0.48
-18.9
0.8
EV-to-EBITDA 0.53
OVAS's EV-to-EBITDA is ranked higher than
94% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. OVAS: 0.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
OVAS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.1  Med: -1 Max: 0.8
Current: 0.53
-19.1
0.8
EV-to-Revenue -78.71
OVAS's EV-to-Revenue is ranked lower than
99.99% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. OVAS: -78.71 )
Ranked among companies with meaningful EV-to-Revenue only.
OVAS' s EV-to-Revenue Range Over the Past 10 Years
Min: -98.8  Med: 109.8 Max: 71966.6
Current: -78.71
-98.8
71966.6
Current Ratio 7.54
OVAS's Current Ratio is ranked higher than
71% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OVAS: 7.54 )
Ranked among companies with meaningful Current Ratio only.
OVAS' s Current Ratio Range Over the Past 10 Years
Min: 6.08  Med: 13.98 Max: 30.5
Current: 7.54
6.08
30.5
Quick Ratio 7.54
OVAS's Quick Ratio is ranked higher than
72% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. OVAS: 7.54 )
Ranked among companies with meaningful Quick Ratio only.
OVAS' s Quick Ratio Range Over the Past 10 Years
Min: 6.08  Med: 13.98 Max: 30.5
Current: 7.54
6.08
30.5
Days Payable 338.15
OVAS's Days Payable is ranked higher than
91% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. OVAS: 338.15 )
Ranked among companies with meaningful Days Payable only.
OVAS' s Days Payable Range Over the Past 10 Years
Min: 147.53  Med: 345.77 Max: 544.01
Current: 338.15
147.53
544.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.70
OVAS's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. OVAS: -26.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OVAS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.3  Med: -26.7 Max: 0
Current: -26.7
-29.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.68
OVAS's Price-to-Net-Cash is ranked higher than
99% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. OVAS: 0.68 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OVAS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.54  Med: 2.67 Max: 21.26
Current: 0.68
0.54
21.26
Price-to-Net-Current-Asset-Value 0.65
OVAS's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. OVAS: 0.65 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OVAS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.53  Med: 2.61 Max: 20.66
Current: 0.65
0.53
20.66
Price-to-Tangible-Book 0.62
OVAS's Price-to-Tangible-Book is ranked higher than
98% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. OVAS: 0.62 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OVAS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.5  Med: 2.55 Max: 19.24
Current: 0.62
0.5
19.24
Price-to-Median-PS-Value 0.34
OVAS's Price-to-Median-PS-Value is ranked higher than
87% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OVAS: 0.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OVAS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.49 Max: 108.53
Current: 0.34
0.24
108.53
Earnings Yield (Greenblatt) % 202.22
OVAS's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. OVAS: 202.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OVAS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11259.3  Med: -11.3 Max: 9665.7
Current: 202.22
-11259.3
9665.7

More Statistics

Revenue (TTM) (Mil) $0.47
EPS (TTM) $ -2.11
Beta4.99
Short Percentage of Float11.49%
52-Week Range $1.25 - 6.43
Shares Outstanding (Mil)35.69

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 0 3 11 55
EPS ($) -1.77 -1.35 -1.20 -0.69
EPS without NRI ($) -1.77 -1.35 -1.20 -0.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}